Similarly, Wertheimeier et al. recently reported that the IL-23/IL-23R axis maintains and stabilizes highly suppressive tumor-associated Tregs, suggesting that IL-23 blockade could be a possible immunotherapeutic strategy [23]. The gene discussed is IL23A; the disease is neoplasm.